X

Drug Profile

UBB 2048

Alternative Names: UBB-2048

Latest Information Update: 10 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UNITY Biotechnology
Class Bispecific antibodies; Eye disorder therapies
Mechanism of Action Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Retinal disorders

Most Recent Events

01 Mar 2024 Unity Biotechnology files for patent protection with United States Patent and Trademark Office for UBB 2048 in USA
03 Oct 2023 Phase-II clinical trials in Retinal disorders in USA (Intravitreous), prior to October 2023 (UNITY Biotechnology pipeline, October 2023)
03 Oct 2023 US FDA approves IND application for UBB 2048 in Retinal disorders, prior to October 2023 (UNITY Biotechnology pipeline, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com